This study complements previous observations that pharmacological inhibition of Tpl2 impairs tumor-associated angiogenesis, blood vessel formation in vivo and VEGF-A-stimulated endothelial cell responses (Lee et al., 2013). Here, MAP3K8 is linked to neoplasm.